This paper, based on an expert report commissioned by Intergenerika, the Swiss association of manufacturers and importers of generics and biosimilars, purports to answer the question of whether this modication is apt to improve the performance of the Swiss healthcare system.
It therefore adopts a much more comprehensive approach than e.g. Toumi et al. [2] who emphasize e ects on HCE. Its starting point is the cost distribution associated with a treatment cycle using a drug that Intergenerika deems realistic for a certain health condition. (Table 1) exhibits the money cost only; the cost of administering the medication borne by patients will be added in (Table 2) below. In view of this generalization, a treatment cycle rather than the DDD (Daily De ned Dose) is used as the unit of reference because the DDD would have entailed time costs amounting to fractions of a minute.
Quellenangabe: Austin Journal of Public Health and Epidemiology